Activated Coagulation FXII: A Unique Target for In Vivo Molecular Imaging
Arteriosclerosis, Thrombosis, and Vascular Biology · 2023
DOI: 10.1161/atvbaha.122.318883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023. Verfasst von Aidan P G Walsh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Theranostics Laboratory (A.P.G.W., E.Y., V.B., X.W.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Carotid Artery Thrombosis, Thrombosis, Pulmonary Embolism. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Current clinical imaging of thromboembolic diseases often relies on indirect detection of thrombi, which may delay diagnosis and ultimately the institution of beneficial, potentially lifesaving treatment. Therefore, the development of targeting tools that facilitate the rapid, specific, and direct imaging of thrombi using molecular imaging is highly sought after. One potential molecular target is FXIIa (factor XIIa), which initiates the intrinsic coagulation pathway but also activates the kallikrein-kinin system, thereby initiating coagulation and inflammatory/immune responses. As FXII (factor XII) is dispensable for normal hemostasis, its activated form (FXIIa) represents an ideal molecular target for diagnostic and therapeutic approaches, the latter combining diagnosis/identification of thrombi and effective antithrombotic therapy.
Methods
We conjugated an FXIIa-specific antibody, 3F7, to a near-infrared (NIR) fluorophore and demonstrated binding to FeCl 3 -induced carotid thrombosis with 3-dimensional fluorescence emission computed tomography/computed tomography and 2-dimensional fluorescence imaging. We further demonstrated ex vivo imaging of thromboplastin-induced pulmonary embolism and detection of FXIIa in human thrombi produced in vitro.
Results
We demonstrated imaging of carotid thrombosis by fluorescence emission computed tomography/computed tomography and measured a significant fold increase in signal between healthy and control vessels from mice injected with 3F7-NIR compared with mice injected with nontargeted probe ( P =0.002) ex vivo. In a model of pulmonary embolism, we measured increased NIR signal in lungs from mice injected with 3F7-NIR compared with mice injected with nontargeted probe ( P =0.0008) and healthy lungs from mice injected with 3F7-NIR ( P =0.021).
Conclusions
Overall, we demonstrate that FXIIa targeting is highly suitable for the specific detection of venous and arterial thrombi. This approach will allow direct, specific, and early imaging of thrombosis in preclinical imaging modalities and may facilitate monitoring of antithrombotic treatment in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging and Theranostics Laboratory (A.P.G.W., E.Y., V.B., X.W.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
- Atherothrombosis and Vascular Biology Laboratory (A.P.G.W., E.Y., J.D.M., V.B., M.J.M., A.H., K.P.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
- Department of Medicine, Monash University, Melbourne, VIC, Australia (A.P.G.W., E.Y., J.D.M., X.W., K.P.).
- Clinical Haematology Department, Alfred Hospital, Melbourne, VIC, Australia (J.D.M.).
- Department of Cardiometabolic Health, University of Melbourne, VIC, Australia (J.D.M., M.J.M., X.W., K.P.).
- CSL, Ltd, Bio21 Institute, Parkville, Melbourne, VIC, Australia (J.F.A., I.L.M., V.R., C.P.).
ORCID-Profile: Aidan P G Walsh, James D McFadyen, Mitchell J Moon, Ineke L Muir, Xiaowei Wang, Karlheinz Peter
Zitieren
APA
Walsh, A. P. G., Yu, E., McFadyen, J. D., Bongcaron, V., Moon, M. J., Huang, A., Arthur, J. F., Muir, I. L., Rayzman, V., Panousis, C., Wang, X., & Peter, K. (2023). Activated Coagulation FXII: A Unique Target for In Vivo Molecular Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.122.318883
Vancouver
Walsh APG, Yu E, McFadyen JD, Bongcaron V, Moon MJ, Huang A, et al. Activated Coagulation FXII: A Unique Target for In Vivo Molecular Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023. doi:10.1161/atvbaha.122.318883
BibTeX
@article{Walsh2023,
author = {Walsh, Aidan P G and Yu, Eefang and McFadyen, James D and Bongcaron, Viktoria and Moon, Mitchell J and Huang, Angela and Arthur, Jane F and Muir, Ineke L and Rayzman, Veronika and Panousis, Con and Wang, Xiaowei and Peter, Karlheinz},
title = {Activated Coagulation FXII: A Unique Target for In Vivo Molecular Imaging},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2023},
doi = {10.1161/atvbaha.122.318883}
}
EUVIMED